Hologic Stock News

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #AI--Hologic's AI-Powered Mammography Technology Flagged a Third of Breast Cancer Cases Initially Interpreted as Negative in Study of 7,500 Screening Exams.

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test.

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #AI--New Clinical Evidence on Hologic's AI-Powered Mammography Solutions Will Be Unveiled at RSNA.

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #cemark--Hologic Introduces Digital Pathology Capabilities With Expanded CE Marking.

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic Announces Financial Results for Fourth Quarter of Fiscal 2025.

We are investigating the fairness of the proposed sale of Hologic to Blackstone and TPG for $76.00 per share in cash and a CVR for up to $3.00 per share.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Hologic, Inc. (NasdaqGS: HOLX) to funds managed by Blackstone and TPG. Under the terms of the proposed transaction, shareholders of Hologic will receive $76.00 per share in cash plus a non-tradable cont...

MILWAUKEE , Oct. 21, 2025 /PRNewswire/ -- The Ademi Firm is investigating Hologic (Nasdaq: HOLX) for possible breaches of fiduciary duty and other violations of law in its transaction with Blackstone and TPG. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.